טוען...
An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder
INTRODUCTION: Vilazodone, a selective and potent 5-HT(1A) partial agonist and 5-HT reuptake inhibitor, has been approved for treatment of major depressive disorder (MDD) in adults. The primary objective of the study was to compare the efficacy and tolerability of switching to 3 different doses of vi...
שמור ב:
| הוצא לאור ב: | Prim Care Companion CNS Disord |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Physicians Postgraduate Press, Inc.
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4664562/ https://ncbi.nlm.nih.gov/pubmed/26693034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4088/PCC.14m01734 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|